GBD 2017 DALYs and HALE Collaborators. Global, regional, and National disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 392, 1859–1922 (2018).
Google Scholar
Oronsky, B. et al. What’s new in SCLC? A review. Neoplasia 19, 842–847 (2017).
Google Scholar
Wang, S. et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci. Rep. 7, 1339 (2017).
Google Scholar
Farago, A. F. & Keane, F. K. Current standards for clinical management of small cell lung cancer. Transl. Lung Cancer Res. 7, 69–79 (2018).
Google Scholar
Jones, G. S. et al. A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung Cancer. 141, 44–55 (2020).
Google Scholar
Jeremic, B. et al. Radiation therapy in extensive stage small cell lung cancer. Front. Oncol. 7, 169 (2017).
Google Scholar
Früh, M. et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Suppl 6, vi99–105 (2013).
Google Scholar
Rudin, C. M. et al. Treatment of small-cell lung cancer: American society of clinical oncology endorsement of the American college of chest physicians guideline. J. Clin. Oncol. 33, 4106–4111 (2015).
Google Scholar
Rossi, A. et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J. Clin. Oncol. 30, 1692–1698 (2012).
Google Scholar
Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929–1939 (2019).
Google Scholar
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Google Scholar
Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220–2229 (2018).
Google Scholar
Cheng, Y. et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 328, 1223–1232 (2022).
Google Scholar
Cheng, Y. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat. Med. 30, 2967–2976 (2024).
Google Scholar
Saltz, L. B. Perspectives on cost and value in cancer care. JAMA Oncol. 2, 19–21 (2016).
Google Scholar
Liu, G. et al. China Guidelines for Pharmacoeconomic Evaluations (China Market, 2020).
Craig, B. A. & Black, M. A. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin. Expert Rev. Pharmacoecon. Outcomes Res. 1, 37–46 (2001).
Google Scholar
Stinnett, A. A. & Mullahy, J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Mak. 18, S68–80 (1998).
Google Scholar
Eichler, H. G. et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 7, 518–528 (2004).
Google Scholar
Guyot, P. et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).
Google Scholar
Andersson, T. M. et al. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med. Res. Methodol. 11, 96 (2011).
Google Scholar
Ouwens, M. J. N. M. et al. Estimating lifetime benefits associated with Immuno-Oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 37, 1129–1138 (2019).
Google Scholar
Royston, P. & Parmar, M. K. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat. Med. 21, 2175–2197 (2002).
Google Scholar
Gu, X. et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 127, 84–89 (2019).
Google Scholar
Yao Zhi Shu Ju. https://db.yaozh.com/yaopinzhongbiao
You, M. et al. Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer. Front. Pharmacol. 13, 1019826 (2022).
Google Scholar
Lu, S. et al. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget 8, 9996–10006 (2017).
Google Scholar
Liang, X. et al. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer. Front. Public. Health. 11, 1156427 (2023).
Google Scholar
Zhou, K., Jiang, C. & Li, Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 136, 98–101 (2019).
Google Scholar
Yang, Z. et al. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Expert Rev. Pharmacoecon. Outcomes Res. 21, 1061–1067 (2021).
Google Scholar
Zheng, Z., Chen, H. & Cai, H. Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer. Front. Oncol. 13, 1259574 (2024).
Google Scholar
Nafees, B. et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac. J. Clin. Oncol. 13, e195–e203 (2017).
Google Scholar
Zhou, K. et al. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clin. Transl. Oncol. 20, 768–774 (2018).
Google Scholar
Nafees, B. et al. Health state utilities for non small cell lung cancer. Health Qual. Life Outcomes. 6, 84 (2008).
Google Scholar
Zhu, Y. et al. First-line immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis. Front. Public. Health. 11, 1028202 (2023).
Google Scholar
Briggs, A. H. et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group-6. Med. Decis. Mak. 32, 722–732 (2012).
Google Scholar
Rudin, C. M. et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J. Clin. Oncol. 38, 2369–2379 (2020).
Google Scholar
Wang, Y. et al. Economic evaluation of first-line atezolizumab for extensive-stage small-cell lung cancer in the US. Front. Public. Health. 9, 650392 (2021).
Google Scholar
Li, L. Y. et al. First-line Atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin. Med. J. (Engl). 132, 2790–2794 (2019).
Google Scholar
Zhou, K. et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 130, 1–4 (2019).
Google Scholar
Liu, G. & Kang, S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev. Pharmacoecon. Outcomes Res. 22, 85–91 (2022).
Google Scholar
Tong, Y. H. et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers’ perspective. Tumori. 108, 33–39 (2022).
Google Scholar
Zhang, L. et al. First-line durvalumab plus platinum-etoposide versus platinum-etoposide for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Front. Oncol. 10, 602185 (2020).
Google Scholar
Ding, D. et al. Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer. J. Natl. Compr. Canc Netw. 19, 1141–1147 (2021).
Google Scholar
Liu, Q. et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. PLoS One. 16, e0258605 (2021).
Google Scholar
Zhu, Y. et al. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a united States-based cost-effectiveness analysis. Cost Eff. Resour. Alloc. 19, 77 (2021).
Google Scholar
link